Trade Report: The Gilead Sciences Inc. (GILD) Position Held by Northside Capital Management LLC

The Gilead Sciences Inc. (GILD) Position Held by Northside Capital Management LLC

Northside Capital Management LLC maintained its position in Gilead Sciences Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel reports. The institutional investor owned 6,787 shares of the biopharmaceutical company’s stock at the end of the second quarter. Northside Capital Management LLC’s holdings in Gilead Sciences were worth $566,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its position in shares of Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock worth $181,075,000 after buying an additional 8,430 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock worth $159,794,000 after buying an additional 258,807 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the last quarter. Temasek Holdings Private Ltd boosted its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the last quarter. Finally, Omega Advisors Inc. purchased a new position in shares of Gilead Sciences during the first quarter worth about $47,491,000. 77.93% of the stock is owned by institutional investors.

Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.04% during midday trading on Thursday, reaching $73.06. The company’s stock had a trading volume of 10,474,362 shares. The firm has a 50 day moving average price of $78.35 and a 200 day moving average price of $84.67. The firm has a market cap of $96.41 billion, a P/E ratio of 6.41 and a beta of 1.10. Gilead Sciences Inc. has a one year low of $72.21 and a one year high of $111.11.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.15 EPS. Equities research analysts forecast that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.57%. Gilead Sciences’s dividend payout ratio is presently 16.56%.

A number of equities analysts have issued reports on GILD shares. Royal Bank Of Canada upped their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, October 3rd. Jefferies Group reduced their price target on Gilead Sciences from $93.00 to $91.00 and set a “hold” rating on the stock in a research report on Wednesday, August 31st. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Monday, September 26th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $108.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 price target on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, September 22nd. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $104.71.

In other news, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the sale, the executive vice president now directly owns 64,122 shares in the company, valued at approximately $5,117,576.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the sale, the insider now owns 4,119,727 shares of the company’s stock, valued at $331,638,023.50. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment